Orca-T Improves cGVHD-Free Survival Across Hematologic Malignancies
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T study.
Related Articles
Exploring the Challenges of Radiopharmaceuticals in Prostate Cancer
Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.
Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma
Preliminary results from the phase 2 IPAX-Linz study show encouraging efficacy and a favorable safety profile for TLX101 in recurrent high-grade glioma.
The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns
Panelists discuss how evolving insights into myelofibrosis—driven by molecular profiling, risk-adaptive therapy, and emerging treatments—are reshaping clinical practice toward more personalized care, with increasing focus…
Participants Discuss PI3K Inhibitors and Endocrine Resistance in Metastatic Breast Cancer
During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor in patients with metastatic breast cancer.
Immunotherapy Inches Forward in Head and Neck Cancer Trials
The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly delineated, even in phase 3 trials.
LAURA Study: NGS Testing in Diagnosis of NSCLC
Panelists discuss how the practice-changing LAURA study demonstrates the critical importance of next-generation sequencing in guiding therapeutic decisions for non–small cell lung cancer (NSCLC) patients.
New Phase in Prostate Cancer Fight: Cu-SAR-bisPSMA Trial Begins
The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant prostate cancer has been dosed.
Fedratinib Shows Promise in Long-Term MPN Success With Tolerable Toxicity
Hany Elmariah, MD, discusses dose-limiting toxicities of fedratinib in a phase 1 study exploring the drug in patients with myeloproliferative neoplasms after HCT.
AI Tool Earns FDA Breakthrough Device Designation in Pancreatic Cancer
The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate its development and approval.
Neoadjuvant Nivolumab/Chemo Shows Promise in HPV-Negative HNSCC
Neoadjuvant nivolumab/chemotherapy followed by response-stratified de-escalated chemoradiation showed strong potential in HPV-negative head and neck cancer.